Neoadjuvant Therapy Clinical Trial
Official title:
Aromatase Inhibitors (AI) Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Treatment in Postmenopausal Hormone Receptor-positive Breast Cancer
The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.
The endocrine therapy has been used more and more in neoadjuvant treatment of hormone receptor-positive breast cancer. But it still a question if neoadjuvant endocrine therapy can be used combined with chemotherapy. There have been several small-sample studies concerning about this item and also got some results that support the suppose that endocrine therapy combined with chemotherapy could rise the effect of neoadjuvant treatment. This study is to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
| Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
| Not yet recruiting |
NCT05983094 -
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04440982 -
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
| Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04588987 -
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT05993858 -
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
|
Phase 2 | |
| Active, not recruiting |
NCT04666090 -
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04848454 -
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
|
Phase 2 | |
| Recruiting |
NCT04062058 -
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06125223 -
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
|
||
| Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05371197 -
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06212440 -
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
|
N/A | |
| Completed |
NCT03178032 -
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
|
Phase 1 |